GW Pharmaceuticals Announces Epidiolex® Receives Fast Track Designation From FDA For The Treatment Of Dravet Syndrome
6/6/2014 9:31:54 AM
LONDON, June 6, 2014 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW," "the Company" or "the Group"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation to GW's investigational cannabidiol (CBD) product, Epidiolex®, in the treatment of Dravet syndrome, a rare and catastrophic treatment-resistant form of childhood epilepsy.
Help employers find you! Check out all the jobs and post your resume.
comments powered by